Allison DeAngelis

FDA Rejects Experimental Rare Blood Cancer Therapy

An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last month, @adamfeuerstein reports. https://t.co/u9gr45Psr9